Search Prime Grants

HT94252310048

Project Grant

Overview

Grant Description
Defining clinically actionable subtypes of castration resistant prostate cancer through epigenetic cell-free DNA analysis.
Awardee
Dana-Farber Cancer Institute
Grant Program (CFDA)
12.420 - Military Medical Research and Development
Awarding / Funding Agency
Defense Health Agency (DHA) [DoD]
Place of Performance
Boston, Massachusetts 021155418 United States
Geographic Scope
Single Zip Code
Related Opportunity
None
Dana-Farber Cancer Institute was awarded Project Grant HT94252310048 worth $1,382,551 from Defense Health Agency in July 2023 with work to be completed primarily in Boston Massachusetts United States. The grant has a duration of 3 years and was awarded through assistance program 12.420 Military Medical Research and Development.

Status
(Ongoing)

Last Modified 6/26/23

Period of Performance
7/1/23
Start Date
6/30/26
End Date
61.0% Complete

Funding Split
$1.4M
Federal Obligation
$0.0
Non-Federal Obligation
$1.4M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to HT94252310048

Subgrant Awards

Disclosed subgrants for HT94252310048

Transaction History

Modifications to HT94252310048

Additional Detail

Award ID FAIN
HT94252310048
SAI Number
None
Award ID URI
None
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Other
Awarding Office
HT9425 ARMY MED RES ACQ ACTIVITY
Funding Office
HT9425 ARMY MED RES ACQ ACTIVITY
Awardee UEI
DPMGH9MG1X67
Awardee CAGE
5E915
Performance District
07
Senators
Edward Markey
Elizabeth Warren
Representative
Ayanna Pressley

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
Defense Health Program, Defense (097-0130) Department of Defense-Military Grants, subsidies, and contributions (41.0) $1,382,551 100%
Modified: 6/26/23